vs
CHAMPIONS ONCOLOGY, INC.（CSBR）与Rumble Inc.（RUM）财务数据对比。点击上方公司名可切换其他公司
Rumble Inc.的季度营收约是CHAMPIONS ONCOLOGY, INC.的1.8倍（$27.1M vs $15.0M），CHAMPIONS ONCOLOGY, INC.净利率更高（1.8% vs -120.8%，领先122.6%），CHAMPIONS ONCOLOGY, INC.同比增速更快（11.5% vs -10.5%），CHAMPIONS ONCOLOGY, INC.自由现金流更多（$-2.0M vs $-31.7M），过去两年Rumble Inc.的营收复合增速更高（15.2% vs 11.8%）
冠军肿瘤学公司是一家成立于2007年的美国科技企业，由约翰霍普金斯大学肿瘤学家David Sidransky博士创立。该公司开发名为TumorGrafts的小鼠模型（又称小鼠化身），可用于测试多种化疗方案、靶向药物与单克隆抗体，帮助为癌症患者筛选潜在的可行治疗方案。
Rumble Inc.是一家加美跨国企业，主营在线视频平台、网络托管及云服务，总部位于加拿大多伦多，美国总部设在佛罗里达州朗博特基。公司由加拿大科技创业者克里斯·帕夫洛夫斯基于2013年创立，云服务板块为Truth Social提供托管支持，其视频平台在美国保守派及极右翼用户群体中广受欢迎，属于“另类科技”阵营。
CSBR vs RUM — 直观对比
损益表 — Q2 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $15.0M | $27.1M |
| 净利润 | $268.0K | $-32.7M |
| 毛利率 | 51.7% | 5.5% |
| 营业利润率 | 1.2% | -131.1% |
| 净利率 | 1.8% | -120.8% |
| 营收同比 | 11.5% | -10.5% |
| 净利润同比 | -63.2% | 86.2% |
| 每股收益（稀释后） | $0.02 | $-0.13 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $15.0M | $27.1M | ||
| Q3 25 | $14.0M | $24.8M | ||
| Q2 25 | $12.4M | — | ||
| Q1 25 | $17.0M | $23.7M | ||
| Q4 24 | $13.5M | $30.2M | ||
| Q3 24 | $14.1M | $25.1M | ||
| Q2 24 | $14.0M | $22.5M | ||
| Q1 24 | $12.0M | $17.7M |
| Q4 25 | $268.0K | $-32.7M | ||
| Q3 25 | $-436.0K | $-16.3M | ||
| Q2 25 | $-1.8M | — | ||
| Q1 25 | $4.5M | $-2.7M | ||
| Q4 24 | $728.0K | $-236.8M | ||
| Q3 24 | $1.3M | $-31.5M | ||
| Q2 24 | $-109.0K | $-26.8M | ||
| Q1 24 | $-2.5M | $-43.3M |
| Q4 25 | 51.7% | 5.5% | ||
| Q3 25 | 42.9% | -1.8% | ||
| Q2 25 | 41.1% | — | ||
| Q1 25 | 61.2% | -26.7% | ||
| Q4 24 | 44.9% | -14.2% | ||
| Q3 24 | 49.7% | -45.4% | ||
| Q2 24 | 48.2% | -58.8% | ||
| Q1 24 | 34.7% | -79.5% |
| Q4 25 | 1.2% | -131.1% | ||
| Q3 25 | -3.8% | -113.6% | ||
| Q2 25 | -16.2% | — | ||
| Q1 25 | 26.4% | -153.5% | ||
| Q4 24 | 5.4% | -80.1% | ||
| Q3 24 | 9.5% | -131.0% | ||
| Q2 24 | -1.9% | -172.7% | ||
| Q1 24 | -21.4% | -197.4% |
| Q4 25 | 1.8% | -120.8% | ||
| Q3 25 | -3.1% | -65.7% | ||
| Q2 25 | -14.9% | — | ||
| Q1 25 | 26.4% | -11.2% | ||
| Q4 24 | 5.4% | -783.2% | ||
| Q3 24 | 9.3% | -125.9% | ||
| Q2 24 | -0.8% | -119.2% | ||
| Q1 24 | -21.1% | -244.1% |
| Q4 25 | $0.02 | $-0.13 | ||
| Q3 25 | $-0.03 | $-0.06 | ||
| Q2 25 | $-0.12 | — | ||
| Q1 25 | $0.31 | $-0.01 | ||
| Q4 24 | $0.05 | $-1.17 | ||
| Q3 24 | $0.09 | $-0.15 | ||
| Q2 24 | $-0.01 | $-0.13 | ||
| Q1 24 | $-0.19 | $-0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $8.5M | $237.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $4.2M | $274.8M |
| 总资产 | $30.2M | $336.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
| Q4 25 | $8.5M | $237.9M | ||
| Q3 25 | $10.3M | $269.8M | ||
| Q2 25 | $9.8M | — | ||
| Q1 25 | $3.2M | $301.3M | ||
| Q4 24 | $2.8M | $114.0M | ||
| Q3 24 | $2.9M | $132.0M | ||
| Q2 24 | $2.6M | $154.2M | ||
| Q1 24 | $4.5M | $183.8M |
| Q4 25 | $4.2M | $274.8M | ||
| Q3 25 | $3.5M | $302.2M | ||
| Q2 25 | $3.8M | — | ||
| Q1 25 | $5.5M | $339.6M | ||
| Q4 24 | $681.0K | $-63.1M | ||
| Q3 24 | $-332.0K | $166.1M | ||
| Q2 24 | $-1.9M | $192.7M | ||
| Q1 24 | $-2.1M | $210.7M |
| Q4 25 | $30.2M | $336.8M | ||
| Q3 25 | $30.5M | $367.2M | ||
| Q2 25 | $32.3M | — | ||
| Q1 25 | $30.6M | $391.1M | ||
| Q4 24 | $25.2M | $195.3M | ||
| Q3 24 | $24.9M | $217.2M | ||
| Q2 24 | $26.1M | $243.2M | ||
| Q1 24 | $26.8M | $263.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.7M | $-29.4M |
| 自由现金流经营现金流 - 资本支出 | $-2.0M | $-31.7M |
| 自由现金流率自由现金流/营收 | -13.1% | -117.2% |
| 资本支出强度资本支出/营收 | 1.6% | 8.5% |
| 现金转化率经营现金流/净利润 | -6.47× | — |
| 过去12个月自由现金流最近4个季度 | $5.6M | $-70.8M |
8季度趋势，按日历期对齐
| Q4 25 | $-1.7M | $-29.4M | ||
| Q3 25 | $600.0K | $-10.6M | ||
| Q2 25 | $6.9M | — | ||
| Q1 25 | $490.0K | $-14.5M | ||
| Q4 24 | $-283.0K | $-12.4M | ||
| Q3 24 | $311.0K | $-19.1M | ||
| Q2 24 | $-1.8M | $-21.7M | ||
| Q1 24 | $-919.0K | $-33.9M |
| Q4 25 | $-2.0M | $-31.7M | ||
| Q3 25 | $554.0K | $-12.0M | ||
| Q2 25 | $6.6M | — | ||
| Q1 25 | $448.0K | $-14.6M | ||
| Q4 24 | $-377.0K | $-12.4M | ||
| Q3 24 | — | $-19.9M | ||
| Q2 24 | $-1.8M | $-23.1M | ||
| Q1 24 | $-1.0M | $-34.3M |
| Q4 25 | -13.1% | -117.2% | ||
| Q3 25 | 4.0% | -48.6% | ||
| Q2 25 | 53.5% | — | ||
| Q1 25 | 2.6% | -61.7% | ||
| Q4 24 | -2.8% | -40.9% | ||
| Q3 24 | — | -79.5% | ||
| Q2 24 | -13.0% | -102.8% | ||
| Q1 24 | -8.4% | -193.3% |
| Q4 25 | 1.6% | 8.5% | ||
| Q3 25 | 0.3% | 5.7% | ||
| Q2 25 | 2.0% | — | ||
| Q1 25 | 0.2% | 0.6% | ||
| Q4 24 | 0.7% | 0.1% | ||
| Q3 24 | 0.0% | 3.4% | ||
| Q2 24 | 0.0% | 6.1% | ||
| Q1 24 | 0.8% | 2.4% |
| Q4 25 | -6.47× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 0.11× | — | ||
| Q4 24 | -0.39× | — | ||
| Q3 24 | 0.24× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSBR
| Pharmacology Services | $14.5M | 97% |
| Other | $520.0K | 3% |
RUM
| Audience Monetization | $23.8M | 88% |
| Other Initiatives | $3.3M | 12% |
